We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

193 hedge funds and large institutions have $581M invested in Sage Therapeutics in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 76 increasing their positions, 54 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

363% more call options, than puts

Call options by funds: $10.1M | Put options by funds: $2.18M

41% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 54

5% less funds holding

Funds holding: 204 → 193 (-11)

8.37% less ownership

Funds ownership: 97.3% → 88.92% (-8.4%)

20% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 40

47% less capital invested

Capital invested by funds: $1.1B → $581M (-$516M)

Holders
193
Holders Change
-11
Holders Change %
-5.39%
% of All Funds
2.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
76
Reduced
54
Closed
40
Calls
$10.1M
Puts
$2.18M
Net Calls
+$7.92M
Net Calls Change
+$5.82M

Top Buyers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$11.1M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$8.59M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$8.52M
4
Invesco
Invesco
Georgia
+$7.38M
5
Renaissance Technologies
Renaissance Technologies
New York
+$6.64M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$60.4M
2
State Street
State Street
Massachusetts
-$25.9M
3
Deutsche Bank
Deutsche Bank
Germany
-$12.9M
4
SC
Samlyn Capital
New York
-$11.1M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
26
Group One Trading
Illinois
$4.34M +$4.65M +362,916 +997%
GIM
27
Granahan Investment Management
Massachusetts
$3.77M +$2.45M +191,158 +122%
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$3.52M +$2.11M +164,933 +104%
American Century Companies
29
American Century Companies
Missouri
$3.44M +$616K +48,041 +18%
TI
30
Trexquant Investment
Connecticut
$3.42M +$3.68M +287,385 +1,032%
Squarepoint
31
Squarepoint
New York
$3.4M +$3.44M +268,549 +599%
PA
32
Pinnacle Associates
New York
$3.18M +$94K +7,334 +3%
JFG
33
Jefferies Financial Group
New York
$3.17M +$693K +54,056 +23%
Hudson Bay Capital Management
34
Hudson Bay Capital Management
Connecticut
$3.16M -$1.08M -84,300 -22%
Ameriprise
35
Ameriprise
Minnesota
$2.98M -$1.09M -84,886 -24%
Jane Street
36
Jane Street
New York
$2.69M +$558K +43,540 +21%
Qube Research & Technologies (QRT)
37
Qube Research & Technologies (QRT)
United Kingdom
$2.54M +$1.64M +127,903 +121%
Millennium Management
38
Millennium Management
New York
$2.54M -$864K -67,464 -22%
PP
39
PDT Partners
New York
$2.54M +$1.16M +90,252 +63%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$2.47M +$1.59M +124,408 +121%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$2.38M +$483K +37,691 +21%
CAC
42
Cowen and Company
New York
$2.33M -$2.8M -218,846 -51%
Two Sigma Investments
43
Two Sigma Investments
New York
$2.31M -$1.49M -115,986 -35%
Capital Fund Management (CFM)
44
Capital Fund Management (CFM)
France
$2.13M +$812K +63,391 +48%
BBA
45
Baker Bros. Advisors
New York
$1.86M -$3.03M -236,191 -58%
Assenagon Asset Management
46
Assenagon Asset Management
Luxembourg
$1.82M +$136K +10,632 +7%
Two Sigma Advisers
47
Two Sigma Advisers
New York
$1.64M +$1.59M +124,099 +468%
N
48
Nuveen
North Carolina
$1.55M – – –
UBS Group
49
UBS Group
Switzerland
$1.52M -$1.48M -115,663 -45%
Verition Fund Management
50
Verition Fund Management
Connecticut
$1.49M -$36.5K -2,847 -2%
1
2
3 4 5

SAGE Hedge Fund Activity: Q2 2024 in Review

193 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2024, worth a combined $581M — down 47% from $1.1B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of SAGE and 32 opened new positions — a net loss of 8 holders — while 54 trimmed existing stakes and 76 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $11.1M. The largest seller was Wellington Management Group, cutting an estimated $60.4M.

  • 193 institutional investors held Sage Therapeutics (SAGE) as of Q2 2024, down from 204 in Q1 2024.
  • Funds reported $581M of Sage Therapeutics stock for Q2 2024, down 47% quarter-over-quarter.
  • 32 funds opened new Sage Therapeutics positions in Q2 2024 and 40 closed out, a net change of -8 holders.
  • The largest Sage Therapeutics buyer in Q2 2024 was Jacobs Levy Equity Management, an estimated $11.1M added.
  • The largest Sage Therapeutics seller in Q2 2024 was Wellington Management Group, an estimated $60.4M sold.

Based on aggregated 13F filings for Q2 2024.